Alzheimer DiseasePhase 2NCT00895895
Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease
A Phase 2 study testing SAM-531 1.5 mg, SAM-531 3.0 mg and SAM-531 5.0 mg in people with Alzheimer Disease, run by Pfizer at 96 sites in 13 countries.
Trial summary
The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels. Subjects will receive either one of the 3 dosage levels of SAM-531, donepezil or placebo for the first 24 weeks of the study (period I). Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Alzheimer Disease
- What is being tested?
- SAM-531 1.5 mg, SAM-531 3.0 mg and SAM-531 5.0 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 526 participants
- Where
- 96 sitesin 13 countries
- Study dates
- May 2009to May 2011
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of probable Alzheimer Disease according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Diseases and Related Disorders Association (NINCDS-ADRDA) criteria.
- Mini-Mental State Examination (MMSE) score of 12 to 24 at screening
- Rosen Modified Hachinski Ischemic score < or equal to 4 at screening.
Who cannot join
- Relevant neurologic disease other than Alzheimer Disease that may affect cognition or ability to complete the study.
- Current major depressive disorder or other current major psychiatric disorder.
- History of clinically evident stroke or clinically important carotid or vertebrobasilar stenosis or plaque.
- Use of prescription or nonprescription medications for cognitive enhancement (including memantine, ginkgo biloba, huperzine A, and cholinesterase inhibitors) within 3 months before the baseline visit.
Trial locations and contacts
96 sites in 13 countries.
96 sites in 13 countries
United States37 sites
Pfizer Investigational Site
Allentown, Pennsylvania, 18104
Pfizer Investigational Site
Atlanta, Georgia, 30308
Pfizer Investigational Site
Atlantis, Florida, 33462
Pfizer Investigational Site
Bennington, Vermont, 05201
Pfizer Investigational Site
Brooksville, Florida, 34601
Pfizer Investigational Site
Cedarhurst, New York, 11516
Pfizer Investigational Site
Costa Mesa, California, 92626
Pfizer Investigational Site
Denver, Colorado, 80218
Pfizer Investigational Site
Denver, Colorado, 80239
Pfizer Investigational Site
Elk Grove Village, Illinois, 60007
Pfizer Investigational Site
Franklin, Tennessee, 37067
Pfizer Investigational Site
Fresno, California, 93720
Pfizer Investigational Site
Garden Grove, California, 92845
Pfizer Investigational Site
Hallandale, Florida, 33009
Pfizer Investigational Site
Long Beach, California, 90806
Pfizer Investigational Site
Miami, Florida, 33180
Pfizer Investigational Site
Middleton, Wisconsin, 53562
Pfizer Investigational Site
Naples, Florida, 34102
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73103
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73112
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73116
Pfizer Investigational Site
Oxnard, California, 93030
Pfizer Investigational Site
Park Ridge, Illinois, 60068
Pfizer Investigational Site
Phoenix, Arizona, 85004
Pfizer Investigational Site
Phoenix, Arizona, 85050
Pfizer Investigational Site
Plantation, Florida, 33317
Pfizer Investigational Site
Portland, Oregon, 97210
Pfizer Investigational Site
St Louis, Missouri, 63104
Pfizer Investigational Site
St Louis, Missouri, 63110
Pfizer Investigational Site
St. Petersburg, Florida, 33702
Pfizer Investigational Site
St. Petersburg, Florida, 33709
Pfizer Investigational Site
Staten Island, New York, 10312
Pfizer Investigational Site
Sunrise, Florida, 33351
Pfizer Investigational Site
Tampa, Florida, 33613
Pfizer Investigational Site
Toledo, Ohio, 43623
Pfizer Investigational Site
Tulsa, Oklahoma, 74104
Pfizer Investigational Site
West Palm Beach, Florida, 33407
Russia12 sites
Pfizer Investigational Site
Kazan', 420101
Pfizer Investigational Site
Moscow, 115522
Pfizer Investigational Site
Moscow, 123182
Pfizer Investigational Site
Nikolskoe Village, Gatchina District, Leningrad Region, 188357
Pfizer Investigational Site
Novosibirsk, 630054
Pfizer Investigational Site
Saint Petersburg, 190005
Pfizer Investigational Site
Saint Petersburg, 192019
Pfizer Investigational Site
Saint Petersburg, 194044
Pfizer Investigational Site
Saint Petersburg, 197022
Pfizer Investigational Site
Saint Petersburg, 198103
Pfizer Investigational Site
Smolensk, 214018
Pfizer Investigational Site
Yaroslavl, 150030
Japan10 sites
Pfizer Investigational Site
Chiba
Pfizer Investigational Site
Fukuoka
Pfizer Investigational Site
Hachiōji, Tokyo
Pfizer Investigational Site
Hiroshima
Pfizer Investigational Site
Kanagawa
Pfizer Investigational Site
Kumamoto
Pfizer Investigational Site
Kyoto
Pfizer Investigational Site
Nagano
Pfizer Investigational Site
Nagasaki
Pfizer Investigational Site
Shizuoka
Romania6 sites
Pfizer Investigational Site
Bucharest, 010825
Pfizer Investigational Site
Bucharest, 011241
Pfizer Investigational Site
Bucharest, 041914
Pfizer Investigational Site
Bucharest, 050098
Pfizer Investigational Site
Craiova, Dolj, 200317
Pfizer Investigational Site
Timișoara, Timiș County, 300736
Chile5 sites
Pfizer Investigational Site
Santiago, Chile, 7500922
Pfizer Investigational Site
Santiago, Chile, 7530193
Pfizer Investigational Site
Santiago, Chile, 7630000
Pfizer Investigational Site
Santiago, Chile, 8330838
Pfizer Investigational Site
Viña del Mar, Chile, 2520997
Colombia5 sites
Pfizer Investigational Site
Bogota, Cundinamarca
Pfizer Investigational Site
Bucamaranga, Santander Department
Pfizer Investigational Site
Cali, Valle del Cauca Department
Pfizer Investigational Site
Pereira, Risaralda Department
Pfizer Investigational Site
Valle Del Cauca
South Africa5 sites
Pfizer Investigational Site
Bellville, Western Cape, 7530
Pfizer Investigational Site
Bloemfontein, Free State, 9301
Pfizer Investigational Site
Cape Town, 7530
Pfizer Investigational Site
Johannesburg, Gauteng, 2196
Pfizer Investigational Site
Pretoria, Gauteng, 0041
Argentina4 sites
Pfizer Investigational Site
C.a.b.a., Buenos Aires, C1126AAB
Pfizer Investigational Site
Caba, Buenos Aires, 1022
Pfizer Investigational Site
Ciudad de Buenos Aires, 1022
Pfizer Investigational Site
Ciudad de Buenos Aires, C1425BWO
Poland4 sites
Pfizer Investigational Site
Krakow, Poland, 31-531
Pfizer Investigational Site
Krakow, 31-531
Pfizer Investigational Site
Poznan, Poland, 61-289
Pfizer Investigational Site
Wroclaw, Poland, 50-088
Hong Kong2 sites
Pfizer Investigational Site
Hong Kong
Pfizer Investigational Site
Shatin, N.T., Hong Kong SAR, China
Mexico2 sites
Pfizer Investigational Site
Aguascalientes, 20127
Pfizer Investigational Site
Saltillo, Coahuila, 25000
New Zealand2 sites
Pfizer Investigational Site
Auckland, 0622
Pfizer Investigational Site
Hamilton, 3240
South Korea2 sites
Pfizer Investigational Site
Seongnam-si, Gyeonggi-do, 463-707
Pfizer Investigational Site
Seoul, 138-736
About this study
Official title: A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease
The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels. Subjects will receive either one of the 3 dosage levels of SAM-531, donepezil or placebo for the first 24 weeks of the study (period I). Subjects who receive placebo for period I will be assigned to receive the highest dose of SAM-531 SAM-531 for the remaining 28 weeks of the study, while subjects who received one of the three SAM-531 dosage levels or donepezil in period I will continue with the same study drug (period II).
Read the detailed description
The study was stopped (date of termination was 13April2011) due to a 6 month interim analysis: all of the 3 SAM-531 dosage levels were declared futile. There were no safety concerns.
- Conditions
- Alzheimer Disease
- Being tested
- Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg, Donepezil
- Medical subject headings
- Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Capsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks.
SAM-531 1.5 mgDrug
Capsules SAM-531 1.5 mg, once a day during 52 weeks.
SAM-531 3.0 mgDrug
Capsules SAM-531 3.0 mg, once a day during 52 weeks.
SAM-531 5.0 mgDrug
Capsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks.
DonepezilDrug
Encapsulated Donepezil 5 mg tablets, once a day during 52 weeks. After Day 42, the dose can up titrated up to 10 mg of Donepezil.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Placebo comparator | Placebo Receives: Drug: Placebo |
| 2 | Experimental | SAM-531 1.5 mg Receives: Drug: SAM-531 1.5 mg |
| 3 | Experimental | SAM-531 3.0 mg Receives: Drug: SAM-531 3.0 mg |
| 4 | Experimental | SAM-531 5.0 mg Receives: Drug: SAM-531 5.0 mg |
| 5 | Active comparator | Donepezil Receives: Drug: Donepezil |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) Total Score at Week 24
14-item scale to assess severity of cognitive impairment in Alzheimer's Disease. Items: word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, recall of test instructions, spoken language ability, word-finding difficulty, comprehension of spoken language, concentration/distractibility, number cancellation and executive maze. Rating scale ranged from 0 (not present) to 5 (severe). Total score was sum of individual scores (items 1-11) and ranged from 0 to 70 with higher scores indicating greater cognitive impairment.
Measured: Baseline, Week 24
Secondary outcomes (19)
Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 24
Caregiver interview-based instrument assessing 10 areas of activities of daily living (ADL) to measure participant's actual performance over the previous 2 weeks. Items included hygiene, dressing, continence, eating, meal preparation, telephoning, outings, finance/correspondence, medications and leisure/housework. Responses scored as 1 (yes) or 0 (no), response of "Not Applicable" was not scored. Total DAD score was sum of scores for 40 items, expressed as a percentage of the number of items answered yes or no. Total score ranged from 0 to 100, higher scores represented less disability in ADL.
Measured: Baseline, Week 24
Change From Baseline in Neuropsychiatry Inventory (NPI) at Week 24
Caregiver interview-based rating scale assessed 10 behavioral, 2 neurovegetative disturbances occurring in dementia: delusions, hallucination, agitation/aggression, depression, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability, aberrant motor behavior, appetite/eating disorders and sleep/nightime behavior disorders. Each symptom score derived by symptom frequency (1 [occasionally] to 4 [very frequently] * symptom severity (1 [mild] to 3 [severe]) and ranged 0-12. Total score = sum of symptom scores; range 0-144, higher score indicating greater behavioral disturbances
Measured: Baseline, Week 24
Number of Participants With Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) Scores at Week 24
Caregiver and participant interview-based tool to rate the overall impression of participant's clinical change of the disease over time. Areas covered in the interview include: relevant history, observation/evaluation, mental/cognitive state, behavior and functioning. Change categorized into 1 of 7 categories: marked improvement, moderate improvement, minimal improvement, no change, minimal worsening, moderate worsening, marked worsening.
Measured: Baseline, Week 24
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associate Learning (PAL)Total Errors (N, Shapes, Adjusted) at Week 24
CANTAB PAL-assessed visual memory/new learning using one or more patterns randomly displayed in boxes on a screen. Participants were to touch the box where patterns first appeared. Stage 1 (practice) and difficulty increased Stage 2 (2 patterns) to Stage 6 (6 patterns). When all locations correctly identified moved to next Stage. Test terminated when a stage could not be completed in 6 attempts. Total Errors=total number of incorrect boxes chosen plus adjustment for estimated possible errors on problems, attempts, and recalls not reached. Total score 0 to 106, lower scores=better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB PAL - Number of Patterns Reached at Week 24
CANTAB PAL-assessed visual memory/new learning using one or more patterns randomly displayed in boxes on a screen. Participants were to touch the box where patterns first appeared. Stage 1 (practice) and difficulty increased Stage 2 (2 patterns) to Stage 6 (6 patterns). When all locations correctly identified moved to next Stage. Test terminated when a stage could not be completed in 6 attempts. Total score was the number of patterns presented at last stage successfully completed and ranged from 2 to 6, higher scores indicated better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB PAL - First Trial Memory Score, Patterns at Week 24
CANTAB PAL-assessed visual memory/new learning using one or more patterns randomly displayed in boxes on a screen. Participants were to touch the box where patterns first appeared. Stage 1 (practice) and difficulty increased Stage 2 (2 patterns) to Stage 6 (6 patterns). When all locations correctly identified moved to next Stage. Test terminated when a stage could not be completed in 6 attempts. Total score was the number of correct choices made on the first attempt at each Stage. Total score ranged from 0 to 20, higher scores indicated better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB Spatial Working Memory (SWM) - Between Errors (4 Boxes) at Week 24
CANTAB-SWM assessed participant's retention of spatial information, ability to manipulate remembered items and strategize. Participant asked to find tokens in on-screen boxes, move them. Difficulty ranged 4-8 boxes to assess, 2 trials per assessment. Between errors: number of times participant revisited a box where a token previously found. In 4 box assessments the maximum number of errors per trial was 20. Test ended with 20 errors in a trial. Less than 20 errors in both trials the participant went to the next level of difficulty. Scores ranged from 0 to 39. Lower scores: better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB-SWM - Between Errors (6 Boxes) at Week 24
CANTAB-SWM assessed participant's retention of spatial information, ability to manipulate remembered items and strategize. Participant asked to find tokens in on-screen boxes, move them. Difficulty ranged 4-8 boxes to assess, 2 trials per assessment. Between errors: number of times participant revisited a box where a token previously found. In 6 box assessments the maximum number of errors per trial was 30. Test ended with 30 errors in a trial. Less than 30 errors in both trials the participant went to the next level of difficulty. Scores ranged from 0 to 59. Lower scores: better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB SWM - Between Errors (8 Boxes) at Week 24
CANTAB-SWM assessed participant's retention of spatial information, ability to manipulate remembered items and strategize. Participant asked to find tokens in on-screen boxes, move them. Difficulty ranged 4-8 boxes to assess, 2 trials per assessment. Between errors: number of times participant revisited a box where a token previously found. In 8 box assessments the maximum number of errors per trial was 40. Test ended with 40 errors in a trial. Less than 40 errors in both trials the participant went to the next level of difficulty. Scores ranged from 0 to 79. Lower scores: better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB SWM - Between Errors (N Boxes) at Week 24
CANTAB-SWM assessed participant's retention of spatial information, ability to manipulate remembered items and strategize. Participant was asked to find tokens in on-screen boxes and move them. Difficulty ranged from 4 to 8 box assessments, 2 trials for each assessment. Possible errors for each successful assessment: 4 box 0-38; 6 box 0-58; 8 box 0-78. Between Errors for N Boxes was the cumulative number of errors per each successful trial. Total scores ranged from 0 to 175. Lower scores indicated better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB SWM Strategy at Week 24
CANTAB-SWM assessed participant's ability to strategize. Participant was asked to find tokens in on-screen boxes and move them. Difficulty ranged from 4 to 8 box assessments, 2 trials per assessment. Strategy score was the number of unique boxes the participant searched in the two 6 and 8 box trials. 6 box trial scores ranged from 1 (1 box searched for all 6 tokens) to 6 (6 boxes searched for 6 tokens). 8 box trial score ranged from 1 (1 box searched) to 8 (8 boxes searched for 8 tokens). Total of the 4 trial scores ranged from 4 to 28. Lower score indicated better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB Pattern Recognition Memory (PRM)-Mean Correct Latency at Week 24
CANTAB-PRM assessed participant's visual pattern recognition memory in a 2-choice forced discrimination paradigm. Participants presented with a series of 12 visual patterns singly. In recognition phase, participants were required to choose between a pattern previously seen and a novel pattern. Patterns in the recognition phase appeared sequentially in reverse order on the screen. Assessment was repeated with 12 new patterns. Latency in correct responses ranged from 0 to infinity millisecond (msec), lower scores indicated better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB PRM-Percentage Correct at Week 24
CANTAB-PRM assessed participant's visual pattern recognition memory in a 2-choice forced discrimination paradigm. Participants presented with a series of 12 visual patterns singly. In recognition phase, participants were required to choose between a pattern previously seen and a novel pattern. Patterns in the recognition phase appeared sequentially in reverse order on the screen. Assessment was repeated with 12 new patterns. Correct response total expressed as a percentage, ranged from 0 to 100, higher scores indicated better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB Reaction Time (RTI) Five-Choice Accuracy at Week 24
CANTAB-RTI assessed participant's reaction, movement time and vigilance during a 5-choice reaction time trial and to measure anticipatory/premature and perseverative responses. In the trial, a yellow spot appeared on a computer screen in 1 of 5 locations, the participant responded by letting go of a press pad and touching the screen where the spot appeared. 5-Choice Accuracy was the total number of trials where participant responded correctly. Total ranged from 0 to 30, higher score indicated better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB RTI Five-Choice Movement Time at Week 24
CANTAB-RTI assessed participant's reaction, movement time and vigilance during 5-choice reaction time trial and also measured anticipatory/premature responses. In the test, a yellow spot appeared on a computer screen in 1 of 5 locations, the participant responded by letting go of a press pad and touching the screen where the spot appeared. 5-Choice Movement Time was the time from release of press pad to screen touch where the spot had been in trials the participant responded correctly. Possible score ranged from 100 to 5100 msec, lower score indicated better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB RTI Five-Choice Reaction Time at Week 24
CANTAB-RTI assessed participant's reaction, movement time and vigilance during 5-choice reaction time trial and also measured anticipatory/premature responses. In the test, a yellow spot appeared on a computer screen in 1 of 5 locations, the participant responded by letting go of a press pad and touching the screen where the spot appeared. 5-Choice Reaction Time was the time from appearance of yellow spot on computer screen to time to release press pad in trials the participant responded correctly. Total ranged from 100 to 5100 (maximum allowed) msec, lower score indicated better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB RTI Simple Movement Time at Week 24
CANTAB-RTI assessed participant's reaction, movement time and vigilance during simple (1 choice) reaction time trial and also measured anticipatory/premature responses. In the test, 1 yellow spot appeared on a computer screen in 1 location, the participant responded by letting go of a press pad and touching the screen where the spot appeared. Simple Movement Time was the time from release of press pad to touch the screen where the spot had been in trials the participant responded correctly. Total ranged from 100 to 5100 (maximum allowed) msec, lower score indicated better performance.
Measured: Baseline, Week 24
Change From Baseline in CANTAB RTI Simple Reaction Time at Week 24
CANTAB-RTI assessed participant's reaction, movement time and vigilance during simple (1 choice) reaction time trial and also measured anticipatory/premature responses. In the test, 1 yellow spot appeared on a computer screen in 1 location, the participant responded by letting go of a press pad and touching the screen where the spot appeared. Simple Reaction Time was the time from appearance of yellow spot on computer screen to time to release press pad in trials the participant responded correctly. Total ranged from 100 to 5100 (maximum allowed) msec, lower score indicated better performance.
Measured: Baseline, Week 24
Percentage of Participants Who Were Responders at Week 24
Responder defined as a participant who demonstrated an improvement of at least 3 points from baseline in the ADAS-Cog total score and no worsening in the DAD total score and in ADCS-CGIC. Participants were considered a responder at Week 24 if all 3 criteria were met.
Measured: Week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2009 (estimated)
- Study startMay 2009
- Primary completionMay 2011
- Study completionMay 2011
Why it stopped: See termination reason in detailed description.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Alzheimer DiseaseStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 526 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00895895
- Sponsor's protocol ID
- 3193A1-2005
- Other IDs
- B1961007
- Status last verified
- Dec 2012
- First submitted
- 7 May 2009
- Last updated
- 31 Jan 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 31 Jan 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease
- ClinicalTrials.gov ID
- NCT00895895
- Acronym / sponsor ID
- 3193A1-2005
- Conditions
- Alzheimer Disease
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: See termination reason in detailed description.
- Enrolment
- 526 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- May 2009
- Primary completion
- May 2011 (actual)
- Study completion
- May 2011 (actual)
- First posted
- 8 May 2009 (estimated)
- Results
- Posted 31 Jan 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels. Subjects will receive either one of the 3 dosage levels of SAM-531, donepezil or placebo for the first 24 weeks of the study (period I). Subjects who receive placebo for period I will be assigned to receive the highest dose of SAM-531 SAM-531 for the remaining 28 weeks of the study, while subjects who received one of the three SAM-531 dosage levels or donepezil in period I will continue with the same study drug (period II).
Detailed description
The study was stopped (date of termination was 13April2011) due to a 6 month interim analysis: all of the 3 SAM-531 dosage levels were declared futile. There were no safety concerns.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| 1 | Placebo comparator | Drug: PlaceboPlacebo |
| 2 | Experimental | Drug: SAM-531 1.5 mgSAM-531 1.5 mg |
| 3 | Experimental | Drug: SAM-531 3.0 mgSAM-531 3.0 mg |
| 4 | Experimental | Drug: SAM-531 5.0 mgSAM-531 5.0 mg |
| 5 | Active comparator | Drug: DonepezilDonepezil |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Diagnosis of probable Alzheimer Disease according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Diseases and Related Disorders Association (NINCDS-ADRDA) criteria.
- Mini-Mental State Examination (MMSE) score of 12 to 24 at screening
- Rosen Modified Hachinski Ischemic score < or equal to 4 at screening.
Key exclusion criteria (4 listed)
- Relevant neurologic disease other than Alzheimer Disease that may affect cognition or ability to complete the study.
- Current major depressive disorder or other current major psychiatric disorder.
- History of clinically evident stroke or clinically important carotid or vertebrobasilar stenosis or plaque.
- Use of prescription or nonprescription medications for cognitive enhancement (including memantine, ginkgo biloba, huperzine A, and cholinesterase inhibitors) within 3 months before the baseline visit.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboCapsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks. | Drug | 1 |
| SAM-531 1.5 mgCapsules SAM-531 1.5 mg, once a day during 52 weeks. | Drug | 2 |
| SAM-531 3.0 mgCapsules SAM-531 3.0 mg, once a day during 52 weeks. | Drug | 3 |
| SAM-531 5.0 mgCapsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks. | Drug | 4 |
| DonepezilEncapsulated Donepezil 5 mg tablets, once a day during 52 weeks. After Day 42, the dose can up titrated up to 10 mg of Donepezil. | Drug | 5 |
Primary outcome
Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) Total Score at Week 24
Time frame: Baseline, Week 24
14-item scale to assess severity of cognitive impairment in Alzheimer's Disease. Items: word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, recall of test instructions, spoken language ability, word-finding difficulty, comprehension of spoken language, concentration/distractibility, number cancellation and executive maze. Rating scale ranged from 0 (not present) to 5 (severe). Total score was sum of individual scores (items 1-11) and ranged from 0 to 70 with higher scores indicating greater cognitive impairment.
19 secondary outcomes
Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Neuropsychiatry Inventory (NPI) at Week 24
Time frame: Baseline, Week 24
Number of Participants With Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) Scores at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associate Learning (PAL)Total Errors (N, Shapes, Adjusted) at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB PAL - Number of Patterns Reached at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB PAL - First Trial Memory Score, Patterns at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB Spatial Working Memory (SWM) - Between Errors (4 Boxes) at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB-SWM - Between Errors (6 Boxes) at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB SWM - Between Errors (8 Boxes) at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB SWM - Between Errors (N Boxes) at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB SWM Strategy at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB Pattern Recognition Memory (PRM)-Mean Correct Latency at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB PRM-Percentage Correct at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB Reaction Time (RTI) Five-Choice Accuracy at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB RTI Five-Choice Movement Time at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB RTI Five-Choice Reaction Time at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB RTI Simple Movement Time at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CANTAB RTI Simple Reaction Time at Week 24
Time frame: Baseline, Week 24
Percentage of Participants Who Were Responders at Week 24
Time frame: Week 24
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jan 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Alzheimer Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
96 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing SAM-531 1.5 mg, SAM-531 3.0 mg and SAM-531 5.0 mg in people with Alzheimer Disease, run by Pfizer at 96 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 31 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 96 sites in United States, Russia, Japan, Romania, Chile and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 31 Jan 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) Total Score at Week 24 (time frame: Baseline, Week 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jan 2013.